ocreb

ONTARIO CANCER RESEARCH ETHICS BOARD
ANNUAL REPORT 2019 – 2020



ALWAYS READY.

Mission

ALWAYS READY TO ADVANCE ETHICALLY SOUND RESEARCH.

About the Ontario Cancer Research Ethics Board

Innovative. Collaborative. Advancing Ethically Sound Research.

Research ethics boards (REBs) are independent, multi-disciplinary committees that review the ethical acceptability of research involving humans. REBs that review biomedical research generally include doctors and other members of the scientific community, as well as non-scientific members with specific expertise, including ethicists, lawyers, privacy experts and members of the general public (community members). The REB's role is to safeguard the rights and welfare of the individuals who volunteer to participate in research, by ensuring that the study sponsor and the researchers have adequately considered and applied the required ethical principles into the design and conduct of the research.

The Ontario Cancer Research Ethics Board (OCREB) has radically changed the research ethics environment for multi-centre cancer trials in Ontario. OCREB is a central, oncology-specialized REB serving the hospitals/cancer centres in Ontario that conduct oncology clinical trials. OCREB's centralized model means that once a study is approved by OCREB, participating study centres can submit their centre-specific applications to OCREB, and typically receive OCREB approval to conduct the study within days. This includes centres joining studies that were originally approved by OCREB months or sometimes years earlier. All participating centres using OCREB must use the same consent form. This model not only provides a robust ethical focus on oncology research, but also streamlines the review process, minimizes redundancy, promotes consistency, and saves the time and cost of having the study reviewed by an REB at every participating institution/study site. Since its first meeting in January 2004, OCREB has been working with researchers, institutions and sponsors to safeguard the rights and welfare of research participants in Ontario, while advancing ethically sound cancer research.

OCREB is accountable to the Ontario Institute for Cancer Research's Board of Directors through the *OCREB Advisory Committee*.

To learn more about OCREB, visit *ocreb.ca*.

ALWAYS READY TO FORGE AHEAD.

Message from the Chairs and Executive Director

A few short months ago, none of us could possibly have imagined such a volatile start to 2020, and the potentially devastating impact of COVID-19 on clinical research. Investigators, institutions, study sponsors, regulators and research ethics boards are scrambling to evaluate a rapidly evolving situation, and mitigate the impact on participant safety and data integrity. Fortunately, OCREB has well-established policies and processes that allow us to continue to function during such an emergency; however, in our wildest dreams we never expected we'd have to resort to them. Thanks to our dedicated OCREB team and research partners, we are forging our way through these extraordinary times.

In an era that is anything but business-as-usual, we remain accountable to you, our stakeholders, and this report highlights some of the brighter moments of pre-COVID 2019-20. One of those moments was hitting a record-breaking number of new studies. For the first time in OCREB's 16-year history, we broke 100 studies, surpassing the previous record of 96 new studies in 2017. While that number might seem low compared to the volume of new studies received by large institutional REBs, as a central REB, OCREB also receives multiple applications on each study from participating centres, making a comparison with other REBs challenging. Despite an 11 per cent increase in overall volume last year, we also are pleased to report that the timeline metrics essentially remain unchanged, and in some cases, improved.

While speed and efficiency are essential components of the OCREB model, quality is key. In that regard, we dedicate a significant amount of our efforts every year on quality improvement activities. One initiative we'd like to highlight was the development of guidelines for the review of studies involving genetic testing. With the increasing tendency for oncology studies to include whole genome sequencing and future unknown testing, a genetics working group was established under the lead of Dr. Jacqueline Limoges, OCREB Vice-Chair. The group involved members of OCREB, including a genetic counsellor, as well as a medical oncologist and a registered nurse with expertise in cancer genetics. The goal of the group was to identify ethical issues related to genetic testing and return of results, and to develop recommendations to guide the OCREB reviews. We thank the working group for their valuable and timely contributions to enhancing OCREB's reviews.

(continued on page 3)

Message (continued)

In news that goes beyond our provincial borders, OCREB has been collaborating with Research Manitoba, CancerCare Manitoba, and the University of Manitoba REB on an REB streamlining pilot project. The results of the pilot will provide the foundation for a larger-scale project aimed at determining the feasibility of a pan-Canadian approach to REB review. Special thanks to Antonia Palmer, a patient advocate and OCREB community member, for spurring on the project. On a related note, we are very excited to report that after a long delay, the national cancer consent form template was finalized in January. We are grateful for Alison van Nie's perseverance in leading the national consent form working group to this important accomplishment. Wide adoption of the template is expected to facilitate REB reviews, and promote consistency in the information provided to research participants in Canada and the U.S. Although there has been informal use of the template in studies submitted to OCREB, the formal launch has been put on hold due to the pandemic.

On the leadership front, we bid farewell at the end of August to Richard Sugarman when his second term as Chair came to an end. Dr. Yoo-Joung (Yooj) Ko, medical oncologist and member of OCREB since 2006 and Vice-Chair since 2013, was appointed as his replacement. In parallel, Dr. Mihaela Mates, medical oncologist and member of OCREB since 2016, was appointed as OCREB Vice-Chair, dividing the duties with Jacqueline Limoges. As Executive Director of OCREB since January 2006, Janet Manzo is the longest OCREB team member "still standing". However, Janet has signaled her intent to retire, or as she says, "embrace a life of adventure as an aspiring bon vivant". We welcome Natascha Kozlowski as Janet's successor. Natascha is an experienced leader with strong skills in clinical research and research ethics, and comes to OCREB from the Durham Regional Cancer Centre at Lakeridge Health, where she was Director of Research. Natascha assumed the role of Executive Director on March 30. Janet will stay on for a short period to facilitate the hand-over.

It was another productive year, and we remain eternally grateful for the unwavering support of the OCREB members, the OCREB office team, and all of our colleagues at OICR and beyond. We are particularly indebted to our colleagues on the front-lines working tirelessly in the eye of the current storm. OCREB is committed to the safety of study participants, and to supporting our oncology research partners as we all navigate these unprecedented times.

Dr. James Wright
Chair, OCREB Advisory Committee

Dr. Yoo-Joung Ko
Chair, OCREB

Ms. Janet Manzo
Executive Director, OCREB

Janet Manzo
Executive Director, OCREB

Message from Janet Manzo, outgoing Executive Director

It is with both excitement and trepidation that after 14 fulfilling years as Executive Director of OCREB, I have decided to step down. I have been involved in the oncology clinical trials world for close to 30 years, and it has been a privilege to work within such a dedicated, talented and supportive community. I am proud of OCREB's accomplishments, and honoured to have worked with so many individuals whose expertise and unfailing commitment have been critical to OCREB's success. Together we have shared some extraordinarily exciting, complex, and challenging times. It will be difficult to leave such a rewarding role. However, I will carry many wonderful memories with me, and watch from the sidelines as OCREB continues to flourish under new leadership. I sincerely hope that OCREB and the entire research enterprise are able to weather the current storm, and emerge relatively unscathed, to continue the challenging and admirable work of advancing ethically sound cancer research.

Message from Natascha Kozlowski, incoming Executive Director

As I accept this role, I must acknowledge the work and success of Janet in her tenure as Executive Director and her leadership in advancing specialized, central research ethics review for multicentre oncology trials. I am proud to continue Janet's work and feel extremely privileged to join an organization with so many dedicated and talented members contributing to excellence in cancer research ethics. I look forward to being part of the many collaborative relationships and fostering continued growth of OCREB in the research ethics community.

Natascha Kozlowski
Incoming Executive Director, OCREB

ALWAYS READY TO MAKE AN IMPACT IN OUR PROVINCE AND BEYOND.

2019 – 2020 Highlights

METRICS

(Data relate to the calendar year)

OCREB received a record number of new studies and the highest overall volume of submissions in its history.

Volume Metrics

OCREB received 105 new studies in 2019 compared to 91 in 2018, and compared to an average of 93 new studies in each the last five years (2015 to 2019). Of the 1,116 studies submitted to OCREB since January 2004, 511 studies associated with 1,496 study-centres remained active at the end of 2019. This compares to 473 and 1,379 respectively, at the same time in 2018, and represents an eight per cent increase in both.

New Studies



Active Studies



Active Study-Centres



Once a study is up and running, it is subject to multiple post-approval submissions. These include applications from centres to join an approved study (centre initial applications), changes related to new information gathered during the conduct of the study (amendments), reports of events that occurred during the study (reportable events), and periodic (at least annual) progress reports (continuing reviews). The table below displays the volume of each application type submitted per year, and the change in volume between 2018 and 2019. The highlighted field shows the year with highest number.

Application Type	2015	2016	2017	2018	2019	% change from 2018
Provincial Initial Applications/New Studies	92	84	96	91	105	+15
Centre Initial Applications	306	294	312	297	299	+1
Provincial Amendments	550	579	709	919	965	+5
Centre Amendments	136	159	167	256	331	+29
Provincial Continuing Reviews	270	310	345	386	454	+18
Centre Continuing Reviews	886	1,043	1,187	1,254	1,488	+19
Provincial Reportable Events	227	229	290	295	267	-9
Centre Reportable Events	193	206	220	241	258	+7
Provincial Study Closures	51	54	46	51	59	+16
Centre Closures	156	163	155	207	198	-4
TOTAL	2,867	3,121	3,527	3,997	4,423	+11

Timeline Metrics

New Studies/Provincial Initial Applications

In 2019, OCREB reviewed 105 new studies: 35 associated with academic/cooperative group sponsors and 70 with industry sponsors. At the time of preparing this report, two studies were not approved yet. Of the 10 studies that met the criteria for delegated review, nine were approved, and within a median time of 9.8 weeks. Of the 95 studies reviewed by the full Board (i.e., at a convened meeting), 94 were approved, and within a median time of 10 weeks. Thirteen were approved within six weeks, including four within four weeks.

Centre Initial Applications

In 2019, OCREB received 299 new centre applications on approved studies. The median time from submission to approval was 3.5 calendar days, which highlights an important benefit of the central REB model. It means that once OCREB issues the study approval, each participating study centre is able to submit an abbreviated centre-specific application and usually receives OCREB approval to conduct the study within days. This includes centres joining studies that were initially approved by OCREB months or sometimes years earlier.

Provincial (Study-Wide) Amendments (PAMs)

OCREB received 965 study amendments in 2019. The median time from submission to approval was under eight weeks for the 124 reviewed by the full board, and four days for the 841 that qualified for delegated review. This represents improvements over the previous two years.

New Studies - Receipt to Approval - 2015 to 2019



Centre Applications - Submission to Approval - 2015 to 2019



Number of PAMs

	Review Type	Submission to Approval (median calendar days)
124	Full Board Review	55 (7.8 weeks)
841	Delegated Review	4 (0.6 weeks)

QUALITY IMPROVEMENT EFFORTS

OCREB dedicates a significant amount of time and effort every year on quality improvement activities. Some of the key activities in 2019–2020 are summarized below.

Policies and Procedures Committee

Established in 2006, this Committee serves as an advisory group to OCREB, with a mandate to investigate emerging issues and to develop relevant policies and procedures. Throughout the year the Committee weighed in on a number of issues such as: the revised Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS2); the Canadian Genetic Non-Discrimination Act; the EU data privacy protection requirements; and most recently, responses to the COVID-19 pandemic. The Committee presents its recommendations to the full Board for information or approval, as applicable.

Genetics Working Group

There is a growing tendency for oncology studies to include genetic testing, whole genome sequencing and future unknown testing. A genetics working group (GWG) was established in January to identify the ethical issues related to genetic testing and the return of results, and to develop recommendations to guide the OCREB reviews. The GWG recommendations were presented at the February and March OCREB meetings, and an algorithm was developed to guide the review process.

Consent Form Audits

Similar to other central REBs – most notably the U.S. NCI Central IRB (NCI CIRB) – for close to 10 years, OCREB has had a controlled honour system for the implementation of consent forms at the participating centres. In this process, OCREB approves the provincial consent forms, which then must adopted by all participating centres. Centres are authorized to apply specific administrative changes, as well as any centre-specific changes that have been pre-approved by OCREB, minimizing unnecessary changes at the centre level, and ensuring that participants in Ontario receive consistent study information. This means that OCREB does not need to review centre-specific consent forms. Instead, periodic audits of signed consent forms are conducted. An audit was conducted last year on 10 per cent of the active studies that had been approved for more than a year. This included 60 centre consent forms in 43 studies – 16 industry and 27 academic. There were no major findings.

OCREB board members and staff participate in various webinars and conferences, as initial and ongoing education is core to REB practices.

Continuing Education

Initial and ongoing education is core to REB practices. OCREB board members and staff participated in various webinars and conferences last year including: the Canadian Association of Research Ethics Boards (CAREB) national meeting in Winnipeg, the University Health Network-sponsored Interaction Conference, the Clinical Trials Ontario (CTO) Annual Conference, and Canadian Cancer Clinical Trial Network (3CTN) Workshops. Nine OCREB members participated in new member ethics orientation sessions. The Chair also encourages the inclusion of education sessions at the monthly OCREB meetings on topics such as: the management of incidental findings, ethical framework for research biopsies in clinical trials, and the national cancer consent form template.

REB Member Role Development

In the absence of clearly-defined roles and responsibilities, REB members may make assumptions about their role based on their background and expertise. In the absence of sufficient available guidelines, OCREB members sought to define the diverse REB member roles and determine how each specialized role contributes to a holistic and effective approach to reviews. Because of a need to determine optimal approaches to the review of drug-related risks, the pharmacist members were the first to engage in this process. The pharmacist/scientist role was examined from the expectations of the pharmacists, as well as the other board members. The role was discussed over a series of meetings, and a framework was presented to the Board at its August meeting. Next to engage in the role review process were the members with relevant legal expertise. One meeting has taken place to date, and additional information is under consideration. This process will continue with each of the REB roles, leading to clarity in the responsibilities, perspectives and expectations that each role brings to the review process.

The combination of a dedicated team and well-established policies and processes allow OCREB to continue its critical role in the protection of research participants.

Exit Interviews

Departing OCREB members are invited to participate in exit surveys designed to assess their experiences in relation to workload, role, responsibilities, and review processes, in particular the ethical criteria guiding the reviews. Responses are summarized and disseminated to the OCREB Advisory Committee and to the OCREB members to establish areas for quality improvement. Five exit interviews were conducted this year. A common recommendation across the interviews was to continue the work on developing the REB member roles.

Pre-Screening Consent Form Project

As a result of inconsistent use of pre-screening consent forms across studies, the OCREB Research Ethics Officer and the pathologist OCREB member developed a pre-screening consent project, commencing with a literature search. The goal of the project was to establish principles for the use of pre-screening consent forms and criteria to guide the OCREB review. The project involved the collection of data from 230 studies reviewed by OCREB in 2015, 2016 and 2018. In 2019, a summer student assisted with collation of the data. Preliminary guidelines have been established for determining when a pre-screening consent is appropriate.

Monthly Webinars/Teleconferences

Since 2006, OCREB has been hosting monthly sessions for study staff at its affiliated centres to provide education, to share noteworthy items affecting the research community and to promote dialogue on research participant protection and to communicate updates on relevant policies regulations and guidelines. Summaries of the sessions are posted on the OCREB website on the *Monthly Centre Meetings* page. Nine sessions were held last year, attended by an average of 14 of the 27 OCREB affiliated centres.

Clinical Trials Ontario REB Qualification

In February 2014, OCREB became the first REB to be qualified under the CTO REB Qualification program. The qualification provides assurances that the REB meets a minimum standard for governance, membership, operations and procedures. As part of maintaining its qualification, OCREB submits a report to CTO annually, and undergoes a qualification assessment every three years. OCREB was re-qualified in February 2020.

HARMONIZATION AND STREAMLINING EFFORTS

Over the last 20 years, several papers have documented the slow pace at which Canada has adapted to the multi-centre research environment. The EU and the U.S. have moved to a single ethics opinion for most multi-centre research. Although there has been considerable advancement towards a single ethics opinion in many provinces, there is no national framework for streamlining or harmonizing research ethics reviews, and Canada is competitively disadvantaged as a result.

Pilot REB Streamlining Project

Streamlining efforts occurring in Manitoba and Ontario created an opportunity for the two provinces to collaborate. Spurred on by the perseverance of a patient advocate, OCREB has joined forces with Research Manitoba, CancerCare Manitoba and the University of Manitoba REB on a pilot REB streamlining project. A pan-Canadian Approach to Research Ethics Review (CARE) Pilot Project Plan was drafted, the project team was identified, and a project kick-off meeting was held in September. The results of the pilot will provide the foundation for a larger scale project aimed at determining the feasibility of a pan-Canadian approach to REB review, and a model or models acceptable to each province.

The project progresses through different review models, identifying and managing barriers and challenges that may arise with each model. Currently, the project is in the Facilitated Review model stage, in which the initial REB conducts a review of the study in compliance with their normal procedures. Following approval, the receiving REB uses the initial REB review materials to facilitate its own review. Subsequently the REBs meet to discuss any material findings. The project is ready to move to the Reciprocal Review model and a Reciprocity Agreement has been executed. The Agreement was modeled after the Saskatchewan, B.C. and Alberta reciprocity agreement. Under this agreement, the receiving REB recognizes the review of the initial reviewing REB, accepts the review, and conducts a delegated review of the study for local context. The receiving REB remains the REB of Record for the study. Three members of the team were accepted to present on the project at the CAREB national conference in April. However, the conference was cancelled due to the pandemic.

Wide adoption of the national consent form will promote consistency in the information provided to research participants across Canada.

National Consent Form Template

The National Consent Form Working Group – chaired by the OCREB Research Ethics Officer – is a joint effort between OCREB and its affiliated Ontario centres, Canadian Cancer Trials Group, the BC Cancer REB, and representatives from organizations in Alberta, Newfoundland, Ontario and Saskatchewan. The mandate of the group is to develop oncology consent form templates that can be adopted by REBs and researchers across Canada and the U.S. The template is a Canadianized version of the U.S. NCI template, which is compliant with the new U.S. Common Rule, and accepted by the FDA. The revisions were for compliance with Canadian requirements and context. The Canadian template also has been adapted for use in pediatrics. Use of the template should foster harmonization, facilitate REB review, and promote consistency in the information provided to research participants across Canada and the U.S. The template was finalized in January 2020. Although there has been informal use of the template, the formal launch has been put on hold due to the pandemic.

COST RECOVERY

OCREB first began charging for the review of industry-sponsored studies in April 2013. As of 2017, OCREB falls under the Clinical Trials Ontario (CTO) structure for the collection and disbursement of the review fees.

OCREB Cost Recovery



A DEDICATED TEAM THAT IS ALWAYS READY TO MEET A CHALLENGE.

OCREB Membership 2019–2020

Chair

Richard Sugarman
Term ended August 2019
Chair, OCREB

Yoo-Joung (Yooj) Ko
Appointed September 1, 2019
Chair, OCREB
Medical Director, Oncology and Endoscopy, St. Michael's Hospital at Unity Health, Toronto
Member, Policies and Procedures Committee
Member, Genetics Working Group

Vice-Chairs

Jacqueline Limoges
Vice-Chair, OCREB
Professor (Nursing), Faculty of Health, Wellness and Science, Georgian College, Barrie
Member, Policies and Procedures Committee
Chair, Genetics Working Group

Mihaela Mates
Appointed September 1, 2019
Vice-Chair, OCREB
Medical Oncologist, Cancer Centre of Southeastern Ontario, Kingston
Member, Policies and Procedures Committee

Members

Natasha Alexander (alternate)
Pediatrician, North York

James Anderson (alternate)
Stepped down September 2019
Bioethicist, The Hospital for Sick Children, Toronto

Kate Besel
Reappointed September 2019
Clinical Research Associate, Sunnybrook Health Sciences Centre, Toronto

Valerie Bourada (alternate)
Research Ethics Board Manager, Children's Hospital of Eastern Ontario, Ottawa

Scott Bratman
Radiation Oncologist, Princess Margaret Cancer Centre, University Health Network, Toronto

Catriona Buick
Advanced Practice Nurse, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto

Lindsay Carlsson
Reappointed July 2019
Clinical Research Coordinator, Princess Margaret Cancer Centre, University Health Network, Toronto
Member, Genetics Working Group

Stephanie Chadwick (alternate)
Nurse Practitioner, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto

Carol Cheung
Pathologist, Princess Margaret Cancer Centre, University Health Network, Toronto
Member, Policies and Procedures Committee

Andrew Choate (alternate)
Community Representative, Garden Hill

Elvina Chow (alternate)
Stepped down September 2019
Lawyer, California
Member, Policies and Procedures Committee

Signy Chow
Hematologist, Sunnybrook Health Sciences Centre, Toronto

Carlo De Angelis (alternate)
Clinician Scientist – Oncology Pharmacy, Sunnybrook Health Sciences Centre, Toronto

Jeff Doi (alternate)
Clinical Trials Pharmacist, Princess Margaret Cancer Centre, University Health Network, Toronto

Christine Elser (alternate)
Medical Oncologist, Princess Margaret Cancer Centre, University Health Network and Mount Sinai Hospital, Toronto

Osvaldo Espin-Garcia (alternate)
Appointed March 1, 2020
Biostatistician, Princess Margaret Cancer Centre, University Health Network, Toronto

Janet Gammon
Pediatric Oncology Nurse (retired), Toronto

Clare Gibbons (alternate)
Appointed November 2019
Manager, Clinical Genetics, North York General Hospital, North York
Member, Genetics Working Group

Ronald Grant (alternate)
Pediatric Medical Oncologist, The Hospital for Sick Children, Toronto

Karen Haas (alternate)
Pediatric Community Representative, Brampton

Michael Huynh
Term completed September 2019
Lawyer, Toronto
Member, Policies and Procedures Committee

Irene Karam (alternate)
Radiation Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto

Swati Kulkarni (alternate)
Medical Oncologist, Windsor Regional Hospital Cancer Program, Windsor

Paula MacDonald (alternate)
Clinical Pharmacist, McMaster Children's Hospital, Hamilton

Arif Manji (alternate)
Pediatric Medical Oncologist, Southlake Regional Health Centre, Newmarket and The Hospital for Sick Children, Toronto

Dr. Yoo-Joung Ko
Chair, OCREB

Dr. Jacqueline Limoges
Vice-Chair, OCREB

Dr. Mihaela Mates
Vice-Chair, OCREB

Andrea Mattiussi
Clinical Pharmacist, The Hospital for Sick Children, Toronto

Melissa McCready
Appointed September 2019
Senior Legal Counsel, Cancer Care Ontario, Toronto

Dolly Menna-Dack (alternate)
Appointed October 2019
Clinical Bioethicist, Holland Bloorview Kids Rehabilitation Hospital, Toronto

Michelle Mullen
Bioethicist, Children's Hospital of Eastern Ontario, Ottawa
Member, Policies and Procedures Committee

Krista Naccarato
Business Coordinator, Clinical Trials, Windsor Regional Hospital, Windsor

Carolyn Nessim
Reappointed February 2020
Surgical Oncologist, The Ottawa Hospital, Ottawa

Antonia Palmer
Pediatric Community Representative, Mississauga
Member, Policies and Procedures Committee

Sameer Parpia (alternate)
Term completed December 31, 2019
Biostatistician, McMaster University, Ontario Clinical Oncology Group, Hamilton

Melody Qu (alternate)
Radiation Oncologist, London Health Sciences Centre, London

Tara Raissi (alternate)
Appointed September 2019
Legal Counsel, La Capitale Insurance and Financial Services Inc., Toronto

Stephen Ronan (alternate)
Appointed September 2019
Partner, Lerners LLP, Toronto

Neda Stjepanovic
Appointed October 2019
Medical Oncologist, Cancer Genetics, Sunnybrook Health Sciences Centre, Toronto
Member, Genetics Working Group

Elizabeth Strevel (alternate)
Medical Oncologist, Trillium Health Partners, Credit Valley Site, Toronto

Mary Stuart
Nurse Practitioner, Princess Margaret Cancer Centre, University Health Network and The Hospital for Sick Children, Toronto

George Tomlinson
Biostatistician, University Health Network and Mount Sinai Hospital, Toronto

Hanna Tseitlin (alternate)
Pediatric Nurse Practitioner, McMaster Children's Hospital, Hamilton

Deborah Van Seters
Reappointed September 2019
Community Representative, Waterloo

Sonal Varma (alternate)
Appointed February 2020
Pathologist, Queen's University and Kingston Health Sciences Centre, Kingston

Lisa Wang (alternate)
Biostatistician, Princess Margaret Cancer Centre, University Health Network, Toronto

Sheila Weitzman
Pediatric Medical Oncologist, The Hospital for Sick Children, Toronto

Jason Yu (alternate)
Reappointed July 2019
Medical Oncologist, Royal Victoria Regional Health Centre, Barrie

OCREB Advisory Committee

Chair

James (Jim) Wright
Associate Professor, McMaster University
Division Head, Radiation Oncology, Juravinski Hospital and Cancer Centre, Hamilton

Members

Josée Bertrand
Principal, The Osborne Group

Laurel Evans
Director, Research Ethics, University of British Columbia, Vancouver

Nancy Walton
Associate Professor, Daphne Cockwell School of Nursing, Ryerson University
Chair, Research Ethics Board, Women's College Hospital, Toronto

Ex-Officio Members

Yooj Ko
Chair, OCREB

Jacqueline Limoges
Vice-Chair, OCREB

Mihaela Mates
Vice-Chair, OCREB

Janet Manzo
Executive Director, OCREB

OCREB Office Personnel

Janet Manzo
Executive Director – *outgoing*
Member, Policies and Procedures Committee

Natascha Kozlowski
Executive Director – *As of March 30, 2020*
Member, Policies and Procedures Committee

Alison van Nie
Research Ethics Officer
Chair, Policies and Procedures Committee
Member, Genetics Working Group

Aurora de Borja
Senior Research Ethics Coordinator
Member, Policies and Procedures Committee
Member, Genetics Working Group

Beren Avci
Research Ethics Coordinator

Carrie Li
As of April 30, 2019
Research Ethics Coordinator

Cindy Sandel
Research Ethics Coordinator

Left to right, OCREB Office Personnel: Cindy Sandel, Carrie Li, Janet Manzo, Alison van Nie and Aurora de Borja
Absent: Beren Avci

ocreb



FOR MORE INFORMATION

Ontario Cancer Research Ethics Board
c/o Ontario Institute for Cancer Research

MaRS Centre
661 University Avenue, Suite 510
Toronto, Ontario M5G 0A3

416-673-6649

ocreb.ca

DESIGN: STOKELY DESIGN ASSOCIATES INC. – *stokelydesign.com*

OICR
Ontario Institute for Cancer Research

OCREB is funded by the Ontario Institute for Cancer Research through funding provided by the Government of Ontario

CLINICAL TRIALS ONTARIO · RESEARCH ETHICS BOARD · CTO QUALIFIED ctontario.ca

OCREB is qualified under the Clinical Trials Ontario REB Qualification Program